Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, March 10, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), Glucagon-like peptide-1 receptor (GLP-1R) has...
RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., March 10, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) and hyposalivation. Xerostomia and hyposalivation are...
China Telecom and Partners Innovate Together! 5G UAV Medical Delivery Network Wins Global Mobile Award
HONG KONG, March 10, 2025 /PRNewswire/ -- On March 5, during the 2025 Mobile World Congress (MWC25), the 5G UAV medical delivery network solution jointly developed by China Telecom, Hangzhou Antwork Network Technology and Zhejiang University was awarded the Global Mobile Award (GLOMO Award) for "Best Mobile Innovation for Connected Health and Wellbeing." This groundbreaking achievement signifies that the integration...
AIM Vaccine’s Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medical Products Administration. This product is an upgraded version of the diploid rabies vaccine,...
U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab) The availability of the first omalizumab biosimilar will help increase access and potentially lower the...
Health In Tech to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
STUART, Fla., March 8, 2025 /PRNewswire/ -- Health In Tech (NASDAQ: HIT), an Insurtech platform company backed by third-party AI technology, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024, following the close of market on Monday, March 17, 2025. Health In Tech...
Whoopi Goldberg Joins United Nations WPHF as Global Patron, Stands in Solidarity with Frontline Women Building Peace
NEW YORK, March 8, 2025 /PRNewswire/ -- The United Nations Women's Peace and Humanitarian Fund (WPHF) is proud to announce that entertainment legend Whoopi Goldberg will serve as WPHF's Global Patron. An iconic actor, producer, and activist, Whoopi's decades-long commitment to social justice, women's rights, and humanitarian causes makes her a natural champion for WPHF's mission to support women...
JungKwanJang to Showcase Functional Red Ginseng Solutions at 2025 Natural Products Expo West
- Global No.1 red ginseng brand JungKwanJang participates in NPEW for 4 consecutive years, introduces new functional red ginseng products- First release of 3 new 'Everytime' products specialized for sports activities… Scheduled to be available on Amazon in March ANAHEIM, Calif., March 7, 2025 /PRNewswire/ -- Global comprehensive health company and No.1 ginseng...
Ping An Tops Global Patentee Top 10 List, Leading in Fintech and Healthcare
Ping An ranks first in global patents in healthcare and fintech, according to two new reports from the Intellectual Property Publishing House. In the fintech sector, Ping An has 8,582 patents, accounting for more than 2% of patents of the entire industry. In the healthcare sector, Ping An holds 4,176 patents, leading among domestic and international patentees....
Nona Biosciences Integrates Cutting-Edge AI Technology to Enhance Its Fully Human Antibody Platform, Accelerating Antibody Discovery Across Key Therapeutic Areas
CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced to unveil its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM. This new platform, powered by advanced artificial intelligence, integrates seamlessly with the company's proprietary Harbour Mice® technology platform,...
